
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2 by 81% in a phase 3 clinical trial conducted with the National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals announced.